Prenetics Global (PRE) – Analysts’ Weekly Ratings Changes

Prenetics Global (NASDAQ: PRE) recently received a number of ratings updates from brokerages and research firms:

• 2/11/2026 – Prenetics Global is now covered by analysts at Roth Mkm. They set a “buy” rating and a $36.00 price target on the stock.
• 2/8/2026 – Prenetics Global was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/31/2026 – Prenetics Global was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/22/2026 – Prenetics Global had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.